United States - English - NLM (National Library of Medicine)

butler animal health supply, llc, d/b/a/ henry schein animal health - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexaject sp is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications : do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

United States - English - NLM (National Library of Medicine)

bimeda, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 3 mg in 1 ml - indications and usage: dexamethasone sodium phosphate injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses. contraindications: do not use in viral infections. except when used for emergency therapy, dexamethasone sodium phosphate is contraindicated in animals with tuberculosis and chronic nephritis. existence of congestive heart failure, osteoporosis and diabetes are relative contraindications. in the presence of infection appropriate antibacterial agents should also be administered and should be continued for at least 3 days after discontinuance of the hormone and disappearance of all signs of infection.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - a. intravenous or intramuscular administration . when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. endocrine disorders . primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or

United States - English - NLM (National Library of Medicine)

cardinal health - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - by intravenous or intramuscular injection when oral therapy is not feasible: 1. endocrine disorders      primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids      where applicable; in infancy, mineralocorticoid supplementation is of particular importance).      acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs      are used).      preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.      shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.      congenital adrenal hyperplasia      nonsuppurative thyroiditis      hypercalcemia associated with cancer 2. rheumatic disorders      as adjunctive therapy for short-term administration (t

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - a. intravenous or intramuscular administration.   when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. endocrine disorders.   primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids      where applicable; in infancy, mineralocorticoid supplementation is of particular importance).      acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice;      mineralocorticoid supplementation may be necessary, particularly when synthetic       analogs are used).      preoperatively, and in the event of serious trauma or illness, in patients with known adrenal       insufficiency or when adrenocortical reserve is doubtful.      shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.      congenital adrenal hyperplasia.      nonsuppurative thyroiditis.      hypercalcemia associated with cancer. 2. rheumatic disorders.  as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:      post-traumatic osteoarthritis.      synovitis of osteoarthritis.      rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require      low-dose maintenance therapy).      acute and subacute bursitis.      epicondylitis.      acute nonspecific tenosynovitis.      acute gouty arthritis.      psoriatic arthritis.      ankylosing spondylitis. 3.   collagen diseases. during an exacerbation or as maintenance therapy in selected cases of:      systemic lupus erythematosus.      acute rheumatic carditis. 4.   dermatologic diseases.      pemphigus.      severe erythema multiforme (stevens-johnson syndrome).      exfoliative dermatitis.      bullous dermatitis herpetiformis.      severe seborrheic dermatitis.      severe psoriasis.      mycosis fungoides. 5. allergic states.   control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:      bronchial asthma.      contact dermatitis.      atopic dermatitis.      serum sickness.      seasonal or perennial allergic rhinitis.      drug hypersensitivity reactions.      urticarial transfusion reactions.      acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. ophthalmic diseases.   severe acute and chronic allergic and inflammatory processes involving the eye, such as:      herpes zoster ophthalmicus.      iritis, iridocyclitis.      chorioretinitis.      diffuse posterior uveitis and choroiditis.      optic neuritis.      sympathetic ophthalmia.      anterior segment inflammation.      allergic conjunctivitis.      allergic corneal marginal ulcers.      keratitis. 7. gastrointestinal diseases.   to tide the patient over a critical period of the disease in:      ulcerative colitis (systemic therapy).      regional enteritis (systemic therapy). 8. respiratory diseases.      symptomatic sarcoidosis.      berylliosis.      fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate       anti-tuberculosis chemotherapy.      loeffler’s syndrome not manageable by other means.      aspiration pneumonitis. 9. hematologic disorders.      acquired (autoimmune) hemolytic anemia.      idiopathic thrombocytopenic purpura in adults      (i.v. only; i.m. administration is contraindicated).      secondary thrombocytopenia in adults.      erythroblastopenia (rbc anemia).      congenital (erythroid) hypoplastic anemia. 10. neoplastic diseases.   for palliative management of:      leukemias and lymphomas in adults.      acute leukemia of childhood. 11. edematous states.   to induce diuresis or remission of proteinuria in the nephrotic syndrome,         without uremia, of the idiopathic type or that due to lupus erythematosus. 12.   nervous system.          acute exacerbations of multiple sclerosis. 13. miscellaneous.      tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy.      trichinosis with neurologic or myocardial involvement.      diagnostic testing of adrenocortical hyperfunction.       cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management. b. intra-articular or soft tissue administration.   when the strength and dosage form of the drug lend      the preparation to the treatment of the condition, those products labeled for intra-articular or soft      tissue administration are indicated as adjunctive therapy for short-term administration     (to tide the patient over an acute episode or exacerbation) in:      synovitis of osteoarthritis.      rheumatoid arthritis.      acute and subacute bursitis.      acute gouty arthritis.      epicondylitis.      acute nonspecific tenosynovitis.      post-traumatic osteoarthritis. c. intralesional administration. when the strength and dosage form of the drug lend the preparation to       the treatment of the condition, those products labeled for intralesional administration are       indicated for:      keloids.      localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus,      psoriatic plaques, granuloma annulare, and lichen simplex chronicus      (neurodermatitis).      discoid lupus erythematosus.      necrobiosis lipoidica diabeticorum.      alopecia areata.      they also may be useful in cystic tumors of an aponeurosis tendon (ganglia). systemic fungal infection.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. congenital adrenal hyperplas

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dexamethasone sodium phosphate - solution for injection/infusion - 4/1 milligram(s)/millilitre - glucocorticoids; dexamethasone

Ireland - English - HPRA (Health Products Regulatory Authority)

taw pharma (ireland) ltd - dexamethasone sodium phosphate - oral solution - 10 mg/5ml - glucocorticoids; dexamethasone

Kenya - English - Pharmacy and Poisons Board

dawa limited p.o box 16633-00620 nairo, kenya - dexamethasone sodium phosphate - injection - dexamethasone sodium phosphate equiv. to… - plain corticosteroids for systemic use:

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmatech cjsc - dexamethasone (dexamethasone sodium phosphate) - solution for injection - 4mg/ml